Streptozotocin, 1982-2022: Forty Years from the FDA's Approval to Treat Pancreatic Neuroendocrine Tumors

Capdevila J, Ducreux M, García Carbonero R, Grande E, Halfdanarson T, Pavel ME, Tafuto S, Welin S, Valentí V, Salazar R (2022)

Publication Type: Journal article, Review article

Publication year: 2022

Journal

Neuroendocrinology Karger

Book Volume: 112

Pages Range: 1155-1167

Journal Issue: 12

DOI: 10.1159/000524988

Abstract

In May 1982, the US Food and Drug Administration (FDA) approved the use of streptozotocin to treat pancreatic neuroendocrine tumors (panNETs). Thus, this year marks 40 years since that landmark date. This review of streptozotocin to treat panNETs is intended to commemorate this anniversary. A historical perspective of the chemical structure, pharmacokinetics, and mechanism of action of streptozotocin is followed by data from prospective and retrospective clinical studies. The last section of the review addresses the latest aspects and takes note of the prospects that lie ahead on the future horizon of the use of streptozotocin to treat panNETs, including ongoing clinical trials.

Authors with CRIS profile

Marianne Ellen Pavel Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology

Involved external institutions

Vall d'Hebron University Hospital / Hospital Universitari Vall d'Hebron ES Spain (ES) Institut Gustave-Roussy FR France (FR) Hospital Universitario 12 de Octubre ES Spain (ES) MD Anderson Cancer Center Madrid ES Spain (ES) Mayo Clinic US United States (USA) (US) Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" IT Italy (IT) Uppsala University Hospital / Akademiska sjukhuset SE Sweden (SE) Hospital Sant Pau i Santa Tecla ES Spain (ES) Catalan Institute of Oncology / Institut Català d'Oncologia (ICO) ES Spain (ES)

How to cite

APA:

Capdevila, J., Ducreux, M., García Carbonero, R., Grande, E., Halfdanarson, T., Pavel, M.E.,... Salazar, R. (2022). Streptozotocin, 1982-2022: Forty Years from the FDA's Approval to Treat Pancreatic Neuroendocrine Tumors. Neuroendocrinology, 112(12), 1155-1167. https://doi.org/10.1159/000524988

MLA:

Capdevila, Jaume, et al. "Streptozotocin, 1982-2022: Forty Years from the FDA's Approval to Treat Pancreatic Neuroendocrine Tumors." Neuroendocrinology 112.12 (2022): 1155-1167.

BibTeX: Download